<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346316</url>
  </required_header>
  <id_info>
    <org_study_id>RSJ10521</org_study_id>
    <nct_id>NCT04346316</nct_id>
  </id_info>
  <brief_title>A Phase II Study in Patients With Alopecia Areata</brief_title>
  <official_title>A Randomized, Double Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 Tablets in Adult Patients With Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reistone Biopharma Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reistone Biopharma Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global Phase 2 study to evaluate the safety and effectiveness of an investigational
      study drug (called SHR0302) in adults with moderate to severe alopecia areata.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is placebo-controlled, meaning that some patients entering the study will not
      receive active study drug but will receive tablets with no active ingredients (a placebo).
      This is a dose-ranging study, investigating 3 different dosing regimens. It will be
      double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will
      not know whether a patient is on active study drug (or the dose) or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change from baseline in Severity of Alopecia Tool (SALT) score</measure>
    <time_frame>week 24</time_frame>
    <description>Severity of alopecia tool is a quantitative assessment of AA severity based on scalp hair loss</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>SHR0302 Dose#1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0302 Dose#2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0302 Dose#3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302</intervention_name>
    <description>Oral tablets taken once daily (QD)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SHR0302 Dose#1</arm_group_label>
    <arm_group_label>SHR0302 Dose#2</arm_group_label>
    <arm_group_label>SHR0302 Dose#3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between 18-65 years of age (both inclusive), at the time of
             informed consent;

          -  Must have moderate to severe alopecia areata.

        Exclusion Criteria:

          -  Other types of alopecia or other diseases that can cause hair loss

          -  Other scalp diseases that could interfere with assessment of hair loss/regrowth

          -  Any previous use of any Janus kinase (JAK) inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zeng Jeremy</last_name>
    <phone>086 21 68813356</phone>
    <email>jeremy.zeng@reistonebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuela Rabiu</last_name>
    <phone>4847444056</phone>
    <email>ella.rabiu@reistonebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novatrials</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2289</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sagi Lior</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skin Health Institute</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter A Foley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodney Sinclair</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

